Back to search results

Accelerated TMS for Adolescent and Young Adult Depression with Suicidal Thoughts

This study is looking at a fast-acting brain stimulation treatment called transcranial magnetic stimulation (TMS) for adolescents and young adults (ages 15-25) who have depression (Major Depressive Disorder or MDD) and suicidal thoughts. TMS is a non-invasive treatment that uses magnetic pulses to stimulate specific areas of the brain. The study will deliver sessions of intermittent theta burst stimulation (iTBS) hourly over 5 days. Researchers want to see if this treatment can reduce depression and suicidal thoughts, and if it is practical and acceptable for patients. The main goal is to measure changes in depression scores after one week. You may be able to join if you speak English, can give informed consent, and have recently been seen for depression-related suicidal ideation.

Study design
This is an interventional study planning to enroll 25 participants. It is not specified if the study is randomized or blinded.
What's involved
Participants will receive hourly transcranial magnetic stimulation (TMS) sessions over 5 days. Brain imaging (MRI) will be used to guide the treatment.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures changes in depression scores at 1 week after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07025720

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

Recruiting
NAAges 15–25InterventionalTreatment
University of California, Davis
~25 participants
Updated 2026-03-11 on ClinicalTrials.gov
What's tested:TMS

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in MADRS score
Measured over 1 week

Conditions

Major Depressive Disorder (MDD)
Suicidal Ideation

Explore related trials

Suicidal IdeationUnipolar Depression

Where it's being run

1 sites across 1 states
California1

Who to contact

Se Ri (Sally) Bae, MD
[email protected]
213-340-4006
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

English speaking
Able to provide informed consent
age 15-25 years
Discharged within the past week from the ED for chief complaint of SI OR recently admitted in urgent health care setting or seen in outpatient clinic for depression-related suicidal ideation
Meets MDD criteria per the Mini International Neuropsychiatric Interview (MINI)

Exclusion

Unable to consent (due to medical condition, psychosis, substance use, etc)
Use of benzodiazepines or medications that would interfere with TMS treatment as per PI discretion
Active substance use or severe substance use that in the opinion of the PI would interfere with study participation
Untreated, active psychosis
Female patient who is breastfeeding, pregnant or who is planning a pregnancy during the study
Participation in any clinical study with exposure to any investigational treatment or product within the previous 30 days, or plan on concurrent participation in other studies
Contraindications to receiving TMS and/or MRI as determined by screening questionnaires

What this trial measures

  • Change in MADRS score1 week

    Change in depressive symptoms as measured by The Montgomery-Åsberg Depression Rating Scale (MADRS) from baseline to post-rTMS treatment. MADRS scores range from 0 to 60, with higher scores reflecting greater severity of depressive symptoms.